The 340B PATIENTS Act of 2025 aims to ensure drug accessibility for covered entities under the 340B drug discount program.
The 340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support Act of 2025, also known as the 340B PATIENTS Act of 2025, seeks to clarify and strengthen the 340B drug discount program. It mandates that drug manufacturers offer discounted prices to covered entities, regardless of the dispensing method or location. The bill also prohibits manufacturers from imposing conditions on covered entities' ability to purchase or use covered outpatient drugs at discounted pricing.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.